0000000000266454

AUTHOR

Valerie Poulart

showing 3 related works from this author

LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction ca…

2020

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentFirst lineEsophageal adenocarcinomaCancerHematologyAdvanced gastric cancerGastroesophageal Junctionmedicine.diseaseOncologyInternal medicinemedicineNivolumabbusinessAnnals of Oncology
researchProduct

LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophagea…

2021

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentFirst lineEsophageal adenocarcinomaCancerIpilimumabHematologyAdvanced gastric cancerGastroesophageal Junctionmedicine.diseaseOncologyInternal medicinemedicineNivolumabbusinessmedicine.drugAnnals of Oncology
researchProduct

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (C…

2021

First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year. We aimed to evaluate first-line programmed cell death (PD)-1 inhibitor-based therapies in gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma. We report the first results for nivolumab plus chemotherapy versus chemotherapy alone.In this multicentre, randomised, open-label, phase 3 trial (CheckMate 649), we enrolled adults (≥18 years) with previously untreated, unresectable, non-HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma, …

Malemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentIpilimumabAdenocarcinoma030204 cardiovascular system & hematologyGastroenterologyCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineProgression-free survivalImmune Checkpoint InhibitorsAgedChemotherapybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseProgression-Free SurvivalOxaliplatinNivolumabFluorouracilAdenocarcinomaDrug Therapy CombinationFemaleEsophagogastric JunctionNivolumabbusinessmedicine.drugThe Lancet
researchProduct